Heli Segersvärd

Heli Segersvärd

Auto-generated profile, based on publicly available information

Heli Segersvärd

Minerva Foundation Institute for Medical Research, 00290 Helsinki, Finland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PLPäivi Lakkisto
Päivi Lakkisto
VKVille Kytö
Ville Kytö
HFHanna Forsten
Hanna Forsten
JSJuha-Matti Siren
Juha-Matti Siren
HSHeli Segersvärd
Heli Segersvärd
ITIlkka Tikkanen
Ilkka Tikkanen

1 January 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HSHeli Segersvärd
Heli Segersvärd
PLPäivi Lakkisto
Päivi Lakkisto
MHMikko Hänninen
Mikko Hänninen
HFHanna Forsten
Hanna Forsten
JSJuuso Siren
Juuso Siren
ITIlkka Tikkanen
Ilkka Tikkanen

Verified
Journal Article
Open access
PDF file
MHMikko Hänninen
Mikko Hänninen
TJToni Jäntti
Toni Jäntti
HTHeli Tolppanen
Heli Tolppanen
HSHeli Segersvärd
Heli Segersvärd
TTTuukka Tarvasmäki
Tuukka Tarvasmäki
FGfor the CardShock Study Group
for the CardShock Study Group
Cardiogenic shock (CS) is a life-threatening emergency. New biomarkers are needed in order to detect patients at greater risk of adverse outcome. Our aim was to assess the characteristics of miR-21-5p, miR-122-5p, and miR-320a-3p in CS and evaluate the value of their expression levels in risk prediction. Circulating levels of miR-21-5p, miR-122-5p, and miR-320a-3p were measured from serial plasma samples of 179 patients during the first 5–10 days after detection of CS, derived from the CardShock study. Acute coronary syndrome was the most common cause (80%) of CS. Baseline (0 h) levels of miR-21-5p, miR-122-5p, and miR-320a-3p were all significantly elevated in nonsurvivors compared to survivors (p < 0.05 for all). Above median levels at 0h of each miRNA were each significantly associated with higher lactate and alanine aminotransferase levels and decreased glomerular filtration rates. After adjusting the multivariate regression analysis with established CS risk factors, miR-21-5p and miR-320a-3p levels above median at 0 h were independently associated with 90-day all-cause mortality (adjusted hazard ratio 1.8 (95% confidence interval 1.1–3.0), p = 0.018; adjusted hazard ratio 1.9 (95% confidence interval 1.2–3.2), p = 0.009, respectively). In conclusion, circulating plasma levels of miR-21-5p, miR-122-5p, and miR-320a-3p at baseline were all elevated in nonsurvivors of CS and associated with markers of hypoperfusion. Above median levels of miR-21-5p and miR-320a-3p at baseline appear to independently predict 90-day all-cause mortality. This indicates the potential of miRNAs as biomarkers for risk assessment in cardiogenic shock.

24 November 2018 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
TJToni Jäntti
Toni Jäntti
HSHeli Segersvärd
Heli Segersvärd
HTHeli Tolppanen
Heli Tolppanen
TTTuukka Tarvasmäki
Tuukka Tarvasmäki
JLJohan Lassus
Johan Lassus
VHVeli-Pekka Harjola
Veli-Pekka Harjola
Aims The role of microRNAs has not been studied in cardiogenic shock. We examined the potential role of miR‐423‐5p level to predict mortality and associations of miR‐423‐5p with prognostic markers in cardiogenic shock. Methods and results We conducted a prospective multinational observational study enrolling consecutive cardiogenic shock patients. Blood samples were available for 179 patients at baseline to determine levels of miR‐423‐5p and other biomarkers. Patients were treated according to local practice. Main outcome was 90 day all‐cause mortality. Median miR‐423‐5p level was significantly higher in 90 day non‐survivors [median 0.008 arbitrary units (AU) (interquartile range 0.003–0.017) vs. 0.004 AU (0.002–0.009), P = 0.003]. miR‐423‐5p level above median was associated with higher lactate (median 3.7 vs. 2.4 mmol/L, P = 0.001) and alanine aminotransferase levels (median 68 vs. 35 IU/L, P < 0.001) as well as lower cardiac index (1.8 vs. 2.4, P = 0.04) and estimated glomerular filtration rate (56 vs. 70 mL/min/1.73 m2, P = 0.002). In Cox regression analysis, miR‐423‐5p level above median was associated with 90 day all‐cause mortality independently of established risk factors of cardiogenic shock [adjusted hazard ratio 1.9 (95% confidence interval 1.2–3.2), P = 0.01]. Conclusions In cardiogenic shock patients, above median level of miR‐423‐5p at baseline is associated with markers of hypoperfusion and seems to independently predict 90 day all‐cause mortality.

Verified
Journal Article
Open access
PDF file
HWHong Wang
Hong Wang
HSHeli Segersvärd
Heli Segersvärd
JSJuuso Siren
Juuso Siren
SPSanni Perttunen
Sanni Perttunen
KIKatariina Immonen
Katariina Immonen
PLPäivi Lakkisto
Päivi Lakkisto
Hyperactive poly(ADP-ribose) polymerases (PARP) promote ischemic heart failure (IHF) after myocardial infarction (MI). However, the role of tankyrases (TNKSs), members of the PARP family, in pathogenesis of IHF remains unknown. We investigated the expression and activation of TNKSs in myocardium of IHF patients and MI rats. We explored the cardioprotective effect of TNKS inhibition in an isoproterenol-induced zebrafish HF model. In IHF patients, we observed elevated TNKS2 and DICER and concomitant upregulation of miR-34a-5p and miR-21-5p in non-infarcted myocardium. In a rat MI model, we found augmented TNKS2 and DICER in the border and infarct areas at the early stage of post-MI. We also observed consistently increased TNKS1 in the border and infarct areas and destabilized AXIN in the infarct area from 4 weeks onward, which in turn triggered Wnt/β-catenin signaling. In an isoproterenol-induced HF zebrafish model, inhibition of TNKS activity with XAV939, a TNKSs-specific inhibitor, protected against ventricular dilatation and cardiac dysfunction and abrogated overactivation of Wnt/β-catenin signaling and dysregulation of miR-34a-5p induced by isoproterenol. Our study unravels a potential role of TNKSs in the pathogenesis of IHF by regulating Wnt/β-catenin signaling and possibly modulating miRNAs and highlights the pharmacotherapeutic potential of TNKS inhibition for prevention of IHF.

29 April 2013 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Open access
PDF file
HSHeli Segersvärd
Heli Segersvärd
PLPäivi Lakkisto
Päivi Lakkisto
HFHanna Forsten
Hanna Forsten
KIKatariina Immonen
Katariina Immonen
RKRiikka Kosonen
Riikka Kosonen
ITIlkka Tikkanen
Ilkka Tikkanen
Introduction: We studied the effects of angiotensin type 1 receptor blockade (ARB) on formation of new cardiomyocytes, neovascularization and ventricular remodelling after myocardial infarction (MI). Methods: Male Wistar rats with MI or sham-operated controls were treated with either losartan or vehicle. Bromodeoxyuridine (BrdU) was given to identify newly formed cardiac cells. Immunohistochemical analysis was used to quantify proliferative and apoptotic cardiomyocytes, vascular structures and c-Kit+ stem/progenitor cells, western blotting to evaluate gene expression, and planimetry and echocardiography to assess cardiac structure and function. Results: The number of BrdU+ cardiomyocytes increased similarly in the vehicle and losartan treated MI groups. The number of apoptotic or proliferating cardiomyocytes did not differ between losartan and vehicle treated rats. Losartan induced an increase in capillary and BrdU+ vascular densities in the infarct border zone. Losartan treatment completely prevented post-MI cardiac hypertrophy. In the non-infarcted myocardium the amount of all BrdU+ cells (including non-cardiomyocyte cells) was highest in the vehicle treated MI rats at week 4. Conclusions: The number of newly formed cardiomyocytes increased after MI. Angiotensin II blockade neither stimulated nor prevented cardiomyocyte regeneration. ARB treatment increased vascular densities in the infarct border zone and modulated remodelling of the non-infarcted myocardium preventing effectively post-MI cardiac hypertrophy.